Julie Gerberding - Merck President
| MRK Stock | EUR 136.80 1.60 1.16% |
President
Dr. Julie Louise Gerberding, M.D. is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck Co., Inc. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Mercks global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Mercks ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations. Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Mercks vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Mercks European vaccine business for which Gerberding is the Board cochair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust nonprofit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories. Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention from 20022009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco . She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. since 2016.
| Age | 63 |
| Tenure | 8 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Julie Gerberding Latest Insider Activity
Tracking and analyzing the buying and selling activities of Julie Gerberding against Merck stock is an integral part of due diligence when investing in Merck. Julie Gerberding insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Julie Gerberding over a year ago Afternext Healthtech exotic insider transaction detected |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | PRESIDENT Age | ||
| James Meer | Elanco Animal Health | 53 | |
| Todd Young | Elanco Animal Health | 51 | |
| Sarena Lin | Elanco Animal Health | 48 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Matthias Heinzel, CEO Board | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Gerhard Schmitz, Head Accounting | ||
| Christine Seidman, Independent Director | ||
| Kathy Warden, Independent Director | ||
| Constantin Fest, Head Relations | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Peter Guenter, CEO Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Marcus Kuhnert, CFO Board | ||
| Peter Wendell, Independent Director | ||
| Friederike Rotsch, Group Compliance | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director | ||
| Dirk Toepfer, Chief Officer | ||
| Pamela Craig, Independent Director | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Kai Beckmann, CEO Board | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.36 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 60.26 % | |||
| Price To Earning | 36.46 X | |||
| Price To Book | 2.77 X | |||
| Price To Sales | 3.80 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.